Improved Drug Susceptibility Testing (DST) for Mycobacteria
Forecasted
This grant funds research to develop faster, more accurate drug susceptibility tests for tuberculosis and non-tuberculous mycobacterial infections to improve treatment and combat rising drug resistance.
Funder: National Institutes of Health
Due Dates (Anticipated): May 2027 (projected)
Funding Amounts: Estimated total program funding: $3,000,000; ~3 awards expected; typical project period up to 5 years.
Summary: Supports development of innovative, rapid, and improved drug susceptibility tests (DSTs) for mycobacterial drugs, including those for tuberculosis and non-tuberculous mycobacterial infections.
Key Information: This is a forecasted opportunity; all dates are projected and subject to change.
Description
The National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, anticipates supporting research to develop improved drug susceptibility tests (DSTs) for mycobacterial drugs. This includes DSTs for drugs currently used in the treatment of tuberculosis (TB) and clinically significant non-tuberculous mycobacterial (NTM) infections, as well as new drugs and those in late-stage clinical development. The initiative aims to address the rising global burden of TB and NTM, the increasing rates of drug-resistant TB, and the limitations of current slow, culture-based DST methods. The program will fund the development of innovative DST assays, including rapid genotypic and improved phenotypic methods that do not require full culture growth, to guide effective treatment and reduce drug resistance and transmission.
